N-methyl-N-((1r,3r)-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)cyclobutyl)acrylamide | 1428775-27-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: N-methyl-N-((1r,3r)-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)cyclobutyl)acrylamide
• CAS: 1428775-27-2
• 化学式: C₂₃H₂₄N₈O₂
• 分子量: 444.496
• InChiKey: FLMFNCJHQKPHDY-WKILWMFISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.05
• 重原子数：
  33.0
• 可旋转键数：
  7.0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  113.85
• 氢给体数：
  2.0
• 氢受体数：
  8.0

反应信息

• 作为产物：
  描述：

  2,4-二氯-5-碘-7-[[2-(三甲基甲硅烷基)乙氧基]甲基]-7h-吡咯并[2,3-d]嘧啶 在 盐酸 、 ammonium hydroxide 、 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 异丙基氯化镁 、 双(三甲基硅烷基)氨基钾 、 caesium carbonate 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 三氟乙酸 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 2-甲基-2-丁醇 、 二氯甲烷 、 水 、 异丙醇 为溶剂， 反应 41.67h， 生成 N-methyl-N-((1r,3r)-3-((2-((1-methyl-1H-pyrazol-4-yl)amino)-5-(pyridin-2-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)cyclobutyl)acrylamide
  参考文献：
  名称：

  Early Process Development of an Irreversible Epidermal Growth Factor Receptor (EGFR) T790 M Inhibitor

  摘要：

  The original synthesis of the irreversible epidermal growth factor receptor (EGFR) T790 M inhibitor 1 was enabled by successful application of ammonium hydroxide to cleanly cleave the N-hydroxymethyl group and by development of high yielding conditions for the subsequent amidation reaction. Furthermore, a protection-free and regioselective new synthetic route was developed that shortened the synthesis from the original 8 steps to 6 steps and improved the overall yield from 5% to 34% on scale. Crystallizations of 1 and intermediates were correspondingly developed to control the quality en route.

  DOI：

  10.1021/acs.oprd.8b00437

文献信息

• SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
  申请人：Signal Pharmaceutical LLC

  公开号：US20140200206A1

  公开（公告）日：2014-07-17

  Provided herein are Pyrrolopyrimidine Compounds having the following structure: wherein R 1 , R 2 , R 3 , and L are as defined herein, compositions comprising an effective amount of a Pyrrolopyrimidine Compound, and methods for treating or preventing breast cancer, more particularly triple negative breast cancer, comprising administering an effective amount of such Pyrrolopyrimidine Compounds to a subject in need thereof.

  本文提供具有以下结构的吡咯吡嘧啶化合物： 其中R1、R2、R3和L如本文所定义，包含有效量吡咯吡嘧啶化合物的组合物，以及治疗或预防乳腺癌，更具体地是三阴性乳腺癌的方法，包括向需要的受试者施用有效量的这种吡咯吡嘧啶化合物。
• PYRROLOPYRIMIDINE AND PURINE DERIVATIVES
  申请人：Cheng Hengmiao

  公开号：US20130079324A1

  公开（公告）日：2013-03-28

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R 1 , R 2 , R 3 , R 4 , R 5 , R 5a , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式（I）的化合物或其药学上可接受的盐，其中Q、T、V、W、X、Y、Z、环A、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17和m在此定义。这些新颖的吡咯嘧啶和嘌呤衍生物在哺乳动物中治疗异常细胞生长，如癌症方面具有用处。另外，本发明还涉及含有这些化合物的药物组合物，以及在哺乳动物中治疗异常细胞生长的方法。
• [EN] PYRROLOPYRIMIDINE AND PURINE DERIVATIVES<br/>[FR] DÉRIVÉS DE PYRROLOPYRIMIDINE ET DE PURINE
  申请人：PFIZER

  公开号：WO2013042006A1

  公开（公告）日：2013-03-28

  The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, T, V, W, X, Y, Z, ring A, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17 and m are defined herein. There novel pyrrolopyrimidine and purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

  本发明涉及式(I)的化合物或其药学上可接受的盐，其中Q、T、V、W、X、Y、Z、环A、R1、R2、R3、R4、R5、R5a、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17和m在此定义。这些新型吡咯并嘧啶和嘌呤衍生物在哺乳动物中用于治疗异常细胞增长，例如癌症。其他实施例涉及含有这些化合物的药物组合物以及使用这些化合物和组合物治疗哺乳动物中的异常细胞增长的方法。
• METHODS OF TREATING A CANCER USING SUBSTITUTED PYRROLOPYRIMIDINE COMPOUNDS, COMPOSITIONS THEREOF
  申请人：Signal Pharmaceuticals, LLC

  公开号：US20160008365A1

  公开（公告）日：2016-01-14

  Provided herein are methods for treating or preventing a cancer, in particular solid tumors and hematological cancers, comprising administering to a subject in need thereof an effective amount of a compound of formula (I):

  本文提供了一种用于治疗或预防癌症的方法，特别是固体肿瘤和血液系统恶性肿瘤，包括向需要治疗的患者施用公式（I）化合物的有效剂量。
• US9040547B2
  申请人：——

  公开号：US9040547B2

  公开（公告）日：2015-05-26